Skip to main content
Livermore
Livermore
ZHEN

Spyre Therapeutics, Inc.

SYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001636282

In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.

Holders of 5% or more of SYRE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Spyre Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of SYRE
HolderLatest formStakeChangeFirst filedLatest filingFiling
Fairmount Funds Management LLC13D/A9.99%9.67M shares0.00 ppfrom 9.99%Jun 30, 20238 filingsJun 23, 2026SEC
BlackRock, Inc.13G/A6.60%3.96M shares–Oct 22, 20243 filingsJul 16, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

89 Schedule 13D and 13G filings on Spyre Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on SYRE
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 14, 2023Deutsch Peter E.13GOld format–New–SEC
Jul 28, 2023Polar Capital Holdings Plc13GOld format–New–SEC
Jul 18, 2023Logos Global Management LP13GOld format–New–SEC
Jul 10, 2023Venrock Healthcare Capital Partners III, L.P.13GOld format–New–SEC
Jul 3, 2023Affinity Asset Advisors, LLC13GOld format–New–SEC
Jun 30, 2023Fairmount Funds Management LLC13DOld format–New–SEC
Jun 30, 2023Deep Track Capital, LP13GOld format–New–SEC
Jun 30, 2023EcoR1 Capital Fund Qualified, L.P.13GOld format–New–SEC
Feb 14, 2023BCLS II Equity Opportunities, LP13G/AOld format–––SEC
Feb 14, 2023Rock Springs Capital Management LP13GOld format–New–SEC
Feb 14, 2023Nantahala Capital Management, LLC13G/AOld format–––SEC
Feb 14, 2023Baker Bros. Advisors LP13GOld format–––SEC
Feb 14, 2023OrbiMed Advisors LLC13G/AOld format–––SEC
Feb 13, 2023Suvretta Capital Management, LLC13G/AOld format–––SEC
Feb 3, 2023Pictet Asset Management SA13GOld format–––SEC
Jan 10, 2023Integrated Core Strategies (US) LLC13G/AOld format–––SEC
Dec 1, 2022Integrated Core Strategies (US) LLC13GOld format–New–SEC
Jun 9, 20223:20 PM ETBlackRock Inc.13GOld format–––SEC
Feb 14, 2022BCLS II Equity Opportunities, LP13G/AOld format–––SEC
Feb 14, 2022Nantahala Capital Management, LLC13GOld format–––SEC
Feb 14, 2022Point72 Asset Management, L.P.13G/AOld format–––SEC
Feb 11, 2022OrbiMed Advisors LLC13G/AOld format–––SEC
Feb 10, 20224:13 PM ETEli Lilly & Co13G/AOld format–––SEC
Feb 10, 2022Pictet Asset Management SA13GOld format–––SEC
Feb 10, 2022Baker Bros. Advisors LP13D/AOld format–––SEC
Feb 10, 2022Adage Capital Partners GP, L.L.C.13G/AOld format–––SEC
Feb 3, 20224:41 PM ETBlackRock Inc.13G/AOld format–––SEC
Dec 16, 2021Suvretta Capital Management, LLC13GOld format–New–SEC
Mar 19, 2021Baker Bros. Advisors LP13D/AOld format–––SEC
Mar 5, 2021Baker Bros. Advisors LP13DOld format–––SEC
Feb 16, 2021Baker Bros. Advisors LP13G/AOld format–––SEC
Feb 16, 2021Nantahala Capital Management, LLC13G/AOld format–––SEC
Feb 16, 2021Point72 Asset Management, L.P.13G/AOld format–––SEC
Feb 12, 2021Lilly Ventures Fund I LLC13GOld format–New–SEC
Feb 12, 2021OrbiMed Advisors LLC13G/AOld format–––SEC
Feb 11, 2021Adage Capital Partners GP, L.L.C.13G/AOld format–––SEC
Feb 10, 2021Pictet Asset Management SA13GOld format–New–SEC
Feb 10, 2021LV Management Group, LLC13G/AOld format–––SEC
Feb 2, 20212:56 PM ETBlackRock Inc.13GOld format–New–SEC

Form 144: proposed insider sales

4 notices from officers, directors and other affiliates planning to sell Spyre Therapeutics, Inc. shares, newest first.

Form 144 notices for SYRE
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Mar 3, 20264:43 PM ETScott BurrowsOfficer10.0K$424.9KMar 3, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Mar 2, 20264:31 PM ETCameron TurtleDirector · Officer60.0K$2.58MMar 2, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Nov 3, 20254:24 PM ETCameron TurtleDirector · Officer90.0K$2.20MNov 3, 202510b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Oct 25, 20244:28 PM ETSessions, LLCDirector7.00K$235.9KOct 25, 202410b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC